
Evox Therapeutics, based in Oxford, UK, is advancing a pipeline of exosome-based therapeutics for a variety of rare diseases, including Niemann Pick Type C. Exosomes are a natural vesicular system the body uses to deliver and transfer materials between cells. Evox is engineering these vesicles to contain NPC1 protein and their deliver to cells has been shown in pre-clinical studies to restore NPC function. Evox has recently partnered with Takeda Pharmaceuticals on its NPC exosome program.

www.evoxtherapeutics.com